Analytical Data
-
Gene name
CST9L
- Application
-
Alternative Names
CST9L；CTES7B；Cystatin-9-like
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9H4G1
-
Expression Region
1-147aa
-
AA Sequence
MLGLPWKGGL SWALLLLLLG SQILLIYAWH FHEQRDCDEH NVMARYLPAT VEFAVHTFNQ QSKDYYAYRL GHILNSWKEQ VESKTVFSME LLLGRTRCGK FEDDIDNCHF QESTELNNTF TCFFTISTRP WMTQFSLLNK TCLEGFH
-
Molecular Weight
41 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CST9L, also known as cystatin-like protein 9, is of significant interest in biomedical research due to its potential role in various physiological and pathological processes, including immune regulation, tissue remodeling, and cancer metastasis. This protein belongs to the cystatin superfamily, which is characterized by its cysteine protease inhibitor activity. The study of CST9L has gained momentum with emerging evidence suggesting its involvement in modulating immune responses and influencing tumorigenesis, making it a potential biomarker and therapeutic target. Recent investigations have focused on the recombinant expression of CST9L to elucidate its functional properties and interactions at the molecular level. By generating a stable and functional form of this protein, researchers aim to dissect its role in cellular pathways and its regulatory effects on proteolytic enzymes. Understanding CST9L's mechanism of action may pave the way for novel therapeutic strategies in treating diseases where immune dysregulation or aberrant proteolysis is implicated. Overall, the ongoing research into CST9L emphasizes its importance in both basic and applied sciences, particularly in the fields of immunology, oncology, and regenerative medicine.
